Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-26T07:46:29.013Z Has data issue: false hasContentIssue false

Chronic psychotic disorder and cognitive decline associated with low-dose interferon-α treatment of hepatitis c: A case report

Published online by Cambridge University Press:  16 April 2020

W. Drozdz
Affiliation:
Clinical Neuropsychology Unit, Nicolaus Copernicus University, Torun, Poland Collegium Medicum, Bydgoszcz, Poland
A. Borkowska
Affiliation:
Clinical Neuropsychology Unit, Nicolaus Copernicus University, Torun, Poland Collegium Medicum, Bydgoszcz, Poland
M. Wilkosc
Affiliation:
Clinical Neuropsychology Unit, Nicolaus Copernicus University, Torun, Poland Collegium Medicum, Bydgoszcz, Poland
M. Tomaszewska
Affiliation:
Clinical Neuropsychology Unit, Nicolaus Copernicus University, Torun, Poland Collegium Medicum, Bydgoszcz, Poland
W. Halota
Affiliation:
Department of Infectious Diseases and Hepatology, Nicolaus Copernicus University, Torun, Poland
M. Pawlowska
Affiliation:
Department of Infectious Diseases and Hepatology, Nicolaus Copernicus University, Torun, Poland
D. Dybowska
Affiliation:
Department of Infectious Diseases and Hepatology, Nicolaus Copernicus University, Torun, Poland
J.K. Rybakowski
Affiliation:
Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Low-dose interferon-α is standard therapy for hepatitis C. Psychotic disorders have been described as a scarce complication of the treatment that resolves with its termination.

Case description:

we present a patient with negative personal and familial psychiatric history who developed serious chronic psychotic disorder with persistent cognitive impairment on the level of dementia after seven month interferon-α therapy. Profound parkinsonian side-effects of neuroleptic treatment accompanied the disturbances.

Conclusions:

Potentially severe brain consequences of long-term low-dose interferon-α therapy for hepatitis C in a susceptible individual may emerge. The underlying cause of the susceptibility remain obscure, however dopaminergic, opioid, serotoninergic and glutaminergic pathways as well as HPA axis hypersensitivity might be supposed. This biological vulnerability might interact with the cytokine's action on brain. Relatively frequent and in some cases serious neuropsychiatric adverse effects of interferon-α therapy indicate the necessity of regular psychiatric consultations during the treatment.

Type
Poster Session 2: Organic Mental Disorders and Memory and Cognitive Dysfunctions
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.